Peringatan Keamanan

LD50=95 mg/kg (rat, IV); LD50=312 mg/kg (mouse, oral); LD50=103 mg/kg (mouse, IV); LD50=250 mg/kg (rabbit, IV)

Procainamide

DB01035

small molecule approved

Deskripsi

A derivative of procaine with less CNS action.

Struktur Molekul 2D

Berat 235.3253
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) ~2.5-4.5 hours
Volume Distribusi * 2 L/kg
Klirens (Clearance) -

Absorpsi

75 to 95%

Metabolisme

Hepatic

Rute Eliminasi

Trace amounts may be excreted in the urine as free and conjugated p-aminobenzoic acid, 30 to 60 percent as unchanged PA, and 6 to 52 percent as the NAPA derivative.

Interaksi Makanan

2 Data
  • 1. Avoid alcohol.
  • 2. Take with food. Food reduces irritation.

Interaksi Obat

1546 Data
Decamethonium The therapeutic efficacy of Decamethonium can be increased when used in combination with Procainamide.
Neosaxitoxin The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Procainamide.
Metocurine iodide The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Procainamide.
Gallamine triethiodide The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Procainamide.
Cisatracurium Procainamide may increase the neuromuscular blocking activities of Cisatracurium.
Rocuronium The therapeutic efficacy of Rocuronium can be increased when used in combination with Procainamide.
Atracurium besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Procainamide.
Doxacurium The therapeutic efficacy of Doxacurium can be increased when used in combination with Procainamide.
Mivacurium The therapeutic efficacy of Mivacurium can be increased when used in combination with Procainamide.
Metocurine The therapeutic efficacy of Metocurine can be increased when used in combination with Procainamide.
Pancuronium The therapeutic efficacy of Pancuronium can be increased when used in combination with Procainamide.
Pipecuronium The therapeutic efficacy of Pipecuronium can be increased when used in combination with Procainamide.
Vecuronium The therapeutic efficacy of Vecuronium can be increased when used in combination with Procainamide.
Rapacuronium The therapeutic efficacy of Rapacuronium can be increased when used in combination with Procainamide.
Atracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Procainamide.
Gallamine The therapeutic efficacy of Gallamine can be increased when used in combination with Procainamide.
Alcuronium The therapeutic efficacy of Alcuronium can be increased when used in combination with Procainamide.
Tubocurarine The therapeutic efficacy of Tubocurarine can be increased when used in combination with Procainamide.
Pyrantel The therapeutic efficacy of Pyrantel can be increased when used in combination with Procainamide.
Fingolimod Fingolimod may increase the arrhythmogenic activities of Procainamide.
Propafenone Propafenone may increase the arrhythmogenic activities of Procainamide.
Cimetidine The serum concentration of Procainamide can be increased when it is combined with Cimetidine.
Dipyridamole The therapeutic efficacy of Procainamide can be decreased when used in combination with Dipyridamole.
Ephedrine Procainamide may increase the neuromuscular blocking activities of Ephedrine.
Bambuterol Procainamide may increase the neuromuscular blocking activities of Bambuterol.
Sar9, Met (O2)11-Substance P Procainamide may increase the neuromuscular blocking activities of Sar9, Met (O2)11-Substance P.
Procaine Procainamide may increase the neuromuscular blocking activities of Procaine.
Chloroprocaine Procainamide may increase the neuromuscular blocking activities of Chloroprocaine.
Trimethaphan Procainamide may increase the neuromuscular blocking activities of Trimethaphan.
Butyrylthiocholine Procainamide may increase the neuromuscular blocking activities of Butyrylthiocholine.
Oxybuprocaine Procainamide may increase the neuromuscular blocking activities of Oxybuprocaine.
Benzonatate Procainamide may increase the neuromuscular blocking activities of Benzonatate.
Ranitidine The serum concentration of Procainamide can be increased when it is combined with Ranitidine.
Succinylcholine The metabolism of Succinylcholine can be decreased when combined with Procainamide.
Mirabegron The serum concentration of Procainamide can be increased when it is combined with Mirabegron.
Sulpiride The risk or severity of adverse effects can be increased when Procainamide is combined with Sulpiride.
Acetyldigitoxin Acetyldigitoxin may increase the arrhythmogenic activities of Procainamide.
Carteolol Procainamide may increase the arrhythmogenic activities of Carteolol.
Tocainide Procainamide may increase the arrhythmogenic activities of Tocainide.
Deslanoside Procainamide may increase the arrhythmogenic activities of Deslanoside.
Metipranolol Procainamide may increase the arrhythmogenic activities of Metipranolol.
Cyclandelate Procainamide may increase the arrhythmogenic activities of Cyclandelate.
Seletracetam Procainamide may increase the arrhythmogenic activities of Seletracetam.
Nylidrin Procainamide may increase the arrhythmogenic activities of Nylidrin.
Dotarizine Procainamide may increase the arrhythmogenic activities of Dotarizine.
Xylometazoline Procainamide may increase the arrhythmogenic activities of Xylometazoline.
Tranilast Procainamide may increase the arrhythmogenic activities of Tranilast.
Fasudil Procainamide may increase the arrhythmogenic activities of Fasudil.
Barnidipine Procainamide may increase the arrhythmogenic activities of Barnidipine.
Azelnidipine Procainamide may increase the arrhythmogenic activities of Azelnidipine.
Cilnidipine Procainamide may increase the arrhythmogenic activities of Cilnidipine.
Darodipine Procainamide may increase the arrhythmogenic activities of Darodipine.
Niludipine Procainamide may increase the arrhythmogenic activities of Niludipine.
Carboxyamidotriazole Procainamide may increase the arrhythmogenic activities of Carboxyamidotriazole.
Naftopidil Procainamide may increase the arrhythmogenic activities of Naftopidil.
Vinpocetine Procainamide may increase the arrhythmogenic activities of Vinpocetine.
Cymarin Procainamide may increase the arrhythmogenic activities of Cymarin.
Metildigoxin Procainamide may increase the arrhythmogenic activities of Metildigoxin.
Tiracizine Procainamide may increase the arrhythmogenic activities of Tiracizine.
Ethacizine Procainamide may increase the arrhythmogenic activities of Ethacizine.
Hydroquinine Procainamide may increase the arrhythmogenic activities of Hydroquinine.
Bioallethrin Procainamide may increase the arrhythmogenic activities of Bioallethrin.
Caroverine Procainamide may increase the arrhythmogenic activities of Caroverine.
Fosfructose Procainamide may increase the arrhythmogenic activities of Fosfructose.
WIN 55212-2 Procainamide may increase the arrhythmogenic activities of WIN 55212-2.
Fish oil Procainamide may increase the arrhythmogenic activities of Fish oil.
Emopamil Procainamide may increase the arrhythmogenic activities of Emopamil.
Lomerizine Procainamide may increase the arrhythmogenic activities of Lomerizine.
Tetrandrine Procainamide may increase the arrhythmogenic activities of Tetrandrine.
Dexniguldipine Procainamide may increase the arrhythmogenic activities of Dexniguldipine.
Fosinoprilat Procainamide may increase the arrhythmogenic activities of Fosinoprilat.
Hydroquinidine Procainamide may increase the arrhythmogenic activities of Hydroquinidine.
SOR-C13 Procainamide may increase the arrhythmogenic activities of SOR-C13.
Dexpropranolol Procainamide may increase the arrhythmogenic activities of Dexpropranolol.
Nimodipine Nimodipine may increase the arrhythmogenic activities of Procainamide.
Atropine Atropine may increase the arrhythmogenic activities of Procainamide.
Adenosine Adenosine may increase the arrhythmogenic activities of Procainamide.
Levosimendan Levosimendan may increase the arrhythmogenic activities of Procainamide.
Prenylamine Procainamide may increase the arrhythmogenic activities of Prenylamine.
Fluspirilene Procainamide may increase the arrhythmogenic activities of Fluspirilene.
Azimilide Procainamide may increase the arrhythmogenic activities of Azimilide.
Tedisamil Procainamide may increase the arrhythmogenic activities of Tedisamil.
Nilvadipine Procainamide may increase the arrhythmogenic activities of Nilvadipine.
Fendiline Procainamide may increase the arrhythmogenic activities of Fendiline.
Eperisone Procainamide may increase the arrhythmogenic activities of Eperisone.
Benidipine Procainamide may increase the arrhythmogenic activities of Benidipine.
Simendan Procainamide may increase the arrhythmogenic activities of Simendan.
Otilonium Procainamide may increase the arrhythmogenic activities of Otilonium.
Nizofenone Procainamide may increase the arrhythmogenic activities of Nizofenone.
Bunaftine Procainamide may increase the arrhythmogenic activities of Bunaftine.
Lorcainide Procainamide may increase the arrhythmogenic activities of Lorcainide.
Penfluridol Procainamide may increase the arrhythmogenic activities of Penfluridol.
Dexverapamil Procainamide may increase the arrhythmogenic activities of Dexverapamil.
Isradipine Isradipine may increase the arrhythmogenic activities of Procainamide.
Trimethadione Trimethadione may increase the arrhythmogenic activities of Procainamide.
Digoxin Digoxin may increase the arrhythmogenic activities of Procainamide.
Hyoscyamine Hyoscyamine may increase the arrhythmogenic activities of Procainamide.
Ethosuximide Ethosuximide may increase the arrhythmogenic activities of Procainamide.
Losartan Losartan may increase the arrhythmogenic activities of Procainamide.
Moricizine Moricizine may increase the arrhythmogenic activities of Procainamide.

Target Protein

Voltage-gated inwardly rectifying potassium channel KCNH2 KCNH2
Sodium channel protein type 5 subunit alpha SCN5A
DNA (cytosine-5)-methyltransferase 1 DNMT1

Referensi & Sumber

Synthesis reference: Victor Chu, Zhu Teng, Steve Goss, Ronald Edwards, Kelle Garvey, Timothy Gorzynski, William Bedzyk, "Synthesis and application of procainamide analogs for use in an immunoassay." U.S. Patent US20050227288, issued October 13, 2005.

Contoh Produk & Brand

Produk: 49 • International brands: 3
Produk
  • Apo-procainamide Cap 250mg
    Capsule • 250 mg • Oral • Canada • Generic • Approved
  • Apo-procainamide Cap 375mg
    Capsule • 375 g • Oral • Canada • Generic • Approved
  • Apo-procainamide Cap 500mg
    Capsule • 500 mg • Oral • Canada • Generic • Approved
  • Procainamide Hci
    Injection, solution • 500 mg/1mL • Intramuscular; Intravenous • US • Generic • Approved
  • Procainamide Hci
    Injection, solution • 100 mg/1mL • Intramuscular; Intravenous • US • Generic • Approved
  • Procainamide Hydrochloride
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
  • Procainamide Hydrochloride
    Capsule • 500 mg/1 • Oral • US • Generic • Approved
  • Procainamide Hydrochloride
    Capsule • 250 mg/1 • Oral • US • Generic • Approved
Menampilkan 8 dari 49 produk.
International Brands
  • Biocoryl
  • Procan
  • Procapan

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul